Pharmion, Celgene merger set to close Friday

By Lisa Kerner

Charlotte, N.C., March 6 - Pharmion Corp. shareholders voted to approve the company's acquisition by Celgene Corp. at a special meeting on Thursday.

The acquisition is now slated to close on Friday.

According to a joint news release, the transaction will bring together the medical therapies Revlimid, Thalomid and Vidaza, generate global revenue streams and accelerate financial growth over the next five years.

As previously reported, Celgene agreed to acquire Pharmion for $72 per share in a cash and stock transaction valued at $2.9 billion.

Pharmion is an oncology company based in Boulder, Colo.

Celgene is a Summit, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.